Selank

Selank is a synthetic tuftsin analog developed in Russia for anxiolytic and nootropic effects; off-label use centers on anxiety relief and cognitive focus, though the community corpus stands at just seven captured reports, all of medium confidence. Clinician guidance points to daily subcutaneous injections of 250–750 mcg, typically cycled for one to three weeks; one source mentions an oral formulation, but subcutaneous delivery remains the prevalent route. It holds no FDA-approved indication, so all human use is off-label or compounded.

Selank

Research Evidence

Evidence shape

Selank sits at the animal-only tier; the sole mapped indication is preclinical mechanistic research, and the record contains zero registered human trials of any kind. Because no trials have been completed, there are no blinded results, no outcomes to parse, and no human evidence to weigh for any mapped indication. That total absence of human testing is the central signal: the compound remains confined to exploratory animal work and has not advanced into clinical investigation.

Depthhow much
0 registered trials
Breadthhow many areas
1 indication mapped
1 animal-only
Qualityhow rigorous
No completed trials
Breadth and depth15 rows captured
Human
direct clinical signal
0
Animal
translational support
12
In vitro
mechanistic support
3
HighMediumLow

Anecdotal efficacy

Side effects

Clinical research side effects

Clinical safety table not projected yet.

Anecdotal side effects

Price

1
UK
2400 mg
$28.58
$0.013/mg
2
US
10 mg
$0.56
$0.056/mg
3
HK
100 mg
$40.00
$0.4/mg
4
US
30 mg
$29.99
$1/mg
5
UK
10 mg
$10.10
$1.01/mg
6
US
100 mg
$152.00
$1.52/mg

price offers can be sorted by column

1-6 of 126

Dosing & Protocol

How Selank is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.

Research trials
Published clinical-trial protocols
Typical dose
No quantified dose captured for this tier.

No structured protocol details captured for this tier yet.

Clinician practice
Doctor & published-protocol guidance · n = 4
Typical dose
300 µg250 µg – 750 µg
250 µg
500 µg
Frequency
daily
Timing
unspecified
Route
subQ
Cycle
unspecified

Clinician protocols dose 250 µg–750 µg daily subQ (4 sources).

4 sources
Anecdotal
Community-reported real-world use · n = 7
Typical dose
No quantified dose captured for this tier.

No structured protocol details captured for this tier yet.

Community reports show Selank is anecdotally used for anxiety reduction (75% positive reports) and cognitive enhancement (100% positive reports). Specific dosage details were not consistently available in the community reports analyzed.

Peptide Deep Dive

Peptide Deep Dive is not projected for this peptide yet.

Peptide feedback

0 forum replies

Live community discussion for Selank, shown here in the site layout and continued on the TVR forum.

Add feedback

No peptide feedback yet

Start the peptide feedback thread on the TVR forum.